Magnification of Asthma by human memory Group 2 Innate lymphoid Cells

Información del proyecto

MAGIC

Identificador del acuerdo de subvención: 798927

DOI

10.3030/798927

Proyecto cerrado

Fecha de la firma de la CE 9 Marzo 2018

Fecha de inicio 1 Septiembre 2018

Fecha de finalización 31 Agosto 2020

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 177 598,80

Aportación de la UE

€ 177 598,80

Coordinado por

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands

Periodic Reporting for period 1 - MAGIC (Magnification of Asthma by human memory Group 2 Innate lymphoid Cells)

Período documentado: 2018-09-01 hasta 2020-08-31

Resumen del contexto y de los objetivos generales del proyecto

Allergen-sensitized individuals may develop chronic inflammation, typically found in asthmatic and atopic dermatitis patients. This process is thought to be mediated by the generation of antigen-specific memory Th2 cells, which respond stronger during subsequent encounters with the same allergen. The characterization of memory T cells has led to the development of vaccination therapies to produce desensitization towards specific antigens. However, these treatments are not always effective as some patients respond to a wide range of allergens in a non-specific manner. The causes for this non- specific allergic response are currently unknown.
This action postulates that Group 2 innate lymphoid cells, critical players in allergic inflammation, fill this gap of knowledge. The researcher showed that allergen-experienced mouse lung ILC2s acquire memory functions: remember previous allergen exposures and react stronger upon subsequent exposure to an unrelated allergen. The goal of this proposal is to demonstrate that human memory ILC2s are involved in atopic dermatitis exacerbation. The supervisor is an expert in human ILCs. Humanized mice will be used to define the phenotype and function of human memory ILC2 and the results will be further validated on peripheral blood and skin samples from healthy and atopic dermatitis patients.
Allergic diseases are highly prevalent worldwide with a substantial social and economic burden due to its high rate of under-diagnosis and under-treatment. Specific focus will be to raise awareness of clinicians and pharmaceutical companies about the potential of memory ILC2 as a target to improve diagnosis and treatment.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

We have analysed skin from healthy individuals and done phenotyping of ILCs by flow citometry. We aim to look for memory ILC2s. Functional in vitro assays suggest memory generation in dermal ILCs.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

scRNA sequencing on human dermal ILCs shows heterogeneity of ILCs. We aim to look for the memory ILC2 subpopulation. We will further correlate frequency of memory ILC2s with the severity of the symptoms on atopic dermatitis patients.

Human dermal ILC2 heterogeneity